EAE. M. Astapenko

E. M. Astapenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. M. Astapenko has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Regulatory Changes in the Circulation of Medicinal Products in the Russian Federation: Legal and Practical Aspects

    by O. G. Nefidova, Kh. B. Baykova, E. M. Astapenko, О. Г. Нефидова, Х. Б. Байкова, Е. М. Астапенко

    In the context of the transition to a common market for medicinal products within the framework of the Eurasian Economic Union (EAEU) and further har monization of national legislation with supranational requirements, assessment of the impact of regulatory framework updates on the development of the Rus sian pharmaceutical sector is of great importance. A sequential analysis of cur rent regulatory legal acts was carried out. Key provisions approved by the new documents that entered into force in the Russian Federation in early 2026 in connection with the transition to the common market for medicinal products in the EAEU include extension of the validity of national registration certifi cates, transition to the unified registration rules in the EAEU, and regulation of the manufacturing and circulation of individual biotechnological medicinal products. These regulatory changes are aimed at creating a balanced system of circulation of medicinal products, on the one hand, ensuring the continuity of the supply of medicinal products to the population and minimizing the risk of shortages of these products, and, on the other hand, improving their quality and safety. Of particular importance is the development of regulatory frame work for personalized medicine, which opens up new opportunities for the treat ment of serious diseases using innovative technologies.

  • Open Access

    Preferential drug program for patients within the federal project for control of cardiovascular diseases: implementation strategy, results and prospects

    by E. G. Kamkin, E. V. Karakulina, E. M. Astapenko, V. A. Gulshina, A. A. Moskalev, A. S. Starovoytova, E. P. Mazygula, Z. N. Tautova, N. E. Zvartau, E. A. Medvedeva, et al.

    A serious barrier to the widespread practical implementation of evidence therapy for cardiovascular diseases is financial constraints, which exacerbate low patient complience and affect inequality in cardiovascular health indicators population, increasing morbidity and mortality. At the level of healthcare systems in different countries, drug provision is recognized as an effective tool for increasing patient adherence to treatment and improving clinical outcomes. The problematic article discusses the preferential drug program within the federal project for control of cardiovascular diseases. The key principles for forming priority groups, mechanisms and stages of program implementation are outlined. Monitoring the program’s effectiveness made it possible to identify reserves and prospects for its further strategic development.